The efficacy, safety, and pharmacokinetics of intramuscular and oral phenyramidol in patients with low back pain in an emergency department

Ergün, Hakan; Polat, Onur; Demirkan, N. Arda; Günalp, Müge; Gürler, Serdar

doi:10.3906/sag-0811-15

“…As a result of the studies, it was determined that both forms had similar efficacy and safety, and it was reported that none of the side effects observed during the study period were at a serious level. 10 In a study examining the efficacy of oral Phenyramidol in 225 patients with dysmenorrhea, the patients were divided into 3 groups: the first group consisted of 75 patients with severe dysmenorrhea between the ages of 16-34; the second group involved 50 female patients between the ages of 16-42 with premenstrual tension headache; in the third group, the efficacy of using phenyramidol in combination compared to the Codeine combination in relieving postpartum pain was evaluated in 100 female patients. In the first group, the participants were initially given 200-400 mg of phenyramidol.…”

Section: Overview Of Clinical Evidencementioning

confidence: 99%

“…9 In another study conducted at Ankara University in 2010, the efficacy, safety, and pharmacokinetic properties of the use of phenyramidol in low back pain were also examined. 10 Apart from these studies, recent studies of phenyramidol in silico, in vitro, and in vivo environments have proven that it has anti-inflammatory activity as well as strong analgesic activity. 11…”

Section: Introductionmentioning

confidence: 99%

Three different pharmacological efficacy in a single molecule- phenyramidol

Faikoglu¹,

Ozcan²,

Saygisever-Faikoglu³

et al. 2022

PPIJ

0

View full text Add to dashboard Cite

Purpose: Phenyramidol was first described pharmacologically in 1959 and is used in the treatment of painful musculoskeletal diseases. In this review, a collective evaluation of in silico, in vitro, in vivo, and clinical studies of Phenyramidol, whose analgesic and myorelaxant efficacy was initially defined, was performed. Our aim was to elucidate the clinical effects, safety, and tolerability profile of Phenyramidol.Method: Literature was retrieved by a PubMed search, using different combinations of pertinent keywords (e.g., phenyramidol, spasm, pain, musculoskeletal disorders), without any limitations in terms of the publication date and language. Papers that assessed the therapeutic efficacy and tolerability of phenyramidol were selected for inclusion according to their relevance for the topic, as judged by the authors. Results:In studies, it has been reported that Phenyramidol exhibits an effective and safe analgesic, myorelaxant and anti-inflammatory activity with equivalent analgesic potency to Codeine and Meperidine. It has been shown that with the use of oral or intramuscular Phenyramidol is an effective and safe treatment option that provides up to 94% improvement in painful musculoskeletal disorders and is tolerable in 96.8% of patients. No addictive effects or serious adverse effects on the cardiovascular system have been observed due to oral, parenteral, or concomitant oral and parenteral use of Phenyramidol. It has been reported in studies that oral phenyramidol does not cause any toxicity, does not have an addictive effect, and does not have any significant side effects on the gastrointestinal system even at daily dosages of up to 3200 mg. No serious side effects or mutagenic effects were observed in patients with the use of phenyramidol, and the incidence of side effects was reported to be similar to that of placebo. It has been observed that phenyramidol has strong anti-inflammatory efficacy in silico, in vitro, and in vivo studies, and in addition to having statistically significant higher analgesic efficacy than thiocolchicoside and acetylsalicylic acid, phenyramidol provides anti-inflammatory efficacy equivalent to Ibuprofen and Dexamethasone through balanced cyclooxygenase enzyme inhibition. Conclusion:Phenyramidol, which contains three pharmacological efficacies that are statistically significant potent analgesic, myorelaxant and anti-inflammatory in studies, is an effective and safe treatment option that provides up to 94% improvement in painful musculoskeletal disorders and is tolerable in 96.8% of patients. Phenyramidol, with its analgesic, myorelaxant and anti-inflammatory effects, is a treatment option that can be used as the first choice in the symptomatic treatment of painful musculoskeletal diseases.

show abstract

“…CV was applied at different potential sweep rates between 10 and 500 mVs −1 in the presence of 0.1 mM PhA at pH 3.0 PB solution on NH 2 fMWCNTs/GCE. The results showed that the both anodic peaks of PhA oxidation are linearly proportional to the scan rate, according to following equations: I P1 (μA) = 0.4472 v (mV s −1 ) + 4.299; r = 0.985 [4] I P2 (μA) = 0.2523 v (mV s −1 ) + 3.0699; r = 0.984 [5] log I P1 (μA) = 1.1907 logv (mV s −1 ) − 0.7139; r = 0.970 [6] log I P2 (μA) = 1.1554 logv (mV s −1 ) − 0.8938; r = 0.970 [7] In addition, the relation between logarithm of peak currents of PhA and logarithm scan rate values showed a linearity with slopes of 1.19 and 1.16, for first and second peaks, respectively. These results indicate the adsorption controlled process.…”

Section: An Electrocatalytic Effect Decreasing the Peak Potential Of ...mentioning

confidence: 99%

“…3 Phenyramidol analysis was performed using liquid chromatography and mass detection. 4 So far, the determination of PhA has not been reported with voltammetric methods. In this work, for the first time we have investigated PhA redox behavior with voltammetric method and its fully validated analysis.…”

mentioning

confidence: 99%

Investigation of Electrochemical Oxidation Mechanism, Thermodynamic Parameters and Sensor Design for Analgesic and Relaxant Drug: Phenyramidol in Aqueous Medium by NH₂fMWCNT

Imanzadeh

¹

,

Bakırhan²,

Habibi

³

et al. 2019

J. Electrochem. Soc.

View full text Add to dashboard Cite

In this study, the electrochemical oxidation mechanism of phenyramidol HCl (PhA) was investigated in aqueous medium. An amine functionalized multi walled carbon nanotube (NH 2 fMWCNT) modified glassy carbon electrode (GCE) was used as a sensitive and fast sensor for the determination of PhA. Scanning electron microscopy (SEM) with Energy Dispersive X-Ray (EDX), analysis and electrochemical impedance spectroscopy (EIS) were applied for investigation of surface morphology. Cyclic voltammetry (CV) differential pulse voltammetry (DPV) and adsorptive stripping differential pulse voltammetry (AdSDPV) methods were employed to compare the redox responses of PhA on the surface of bare and modified electrode with NH 2 fMWCNTs. The results showed a considerable enhancement in the peak current of PhA with AdSDPV. A linear calibration curve was obtained in the concentration ranges of 0.8-100 μM, with a detection limit of 6.13 × 10 −8 M and 2.78 × 10 −8 M from peaks 1 and 2, respectively. The proposed procedure was easily and sensitively applied for the determination of PhA in human serum samples and tablet dosage form with satisfactory recovery value (recovery >99%).

show abstract

Untitled

2022

PPIJ

0

View full text Add to dashboard Cite

Purpose: Phenyramidol was first described pharmacologically in 1959 and is used in the treatment of painful musculoskeletal diseases. In this review, a collective evaluation of in silico, in vitro, in vivo, and clinical studies of Phenyramidol, whose analgesic and myorelaxant efficacy was initially defined, was performed. Our aim was to elucidate the clinical effects, safety, and tolerability profile of Phenyramidol.Method: Literature was retrieved by a PubMed search, using different combinations of pertinent keywords (e.g., phenyramidol, spasm, pain, musculoskeletal disorders), without any limitations in terms of the publication date and language. Papers that assessed the therapeutic efficacy and tolerability of phenyramidol were selected for inclusion according to their relevance for the topic, as judged by the authors. Results:In studies, it has been reported that Phenyramidol exhibits an effective and safe analgesic, myorelaxant and anti-inflammatory activity with equivalent analgesic potency to Codeine and Meperidine. It has been shown that with the use of oral or intramuscular Phenyramidol is an effective and safe treatment option that provides up to 94% improvement in painful musculoskeletal disorders and is tolerable in 96.8% of patients. No addictive effects or serious adverse effects on the cardiovascular system have been observed due to oral, parenteral, or concomitant oral and parenteral use of Phenyramidol. It has been reported in studies that oral phenyramidol does not cause any toxicity, does not have an addictive effect, and does not have any significant side effects on the gastrointestinal system even at daily dosages of up to 3200 mg. No serious side effects or mutagenic effects were observed in patients with the use of phenyramidol, and the incidence of side effects was reported to be similar to that of placebo. It has been observed that phenyramidol has strong anti-inflammatory efficacy in silico, in vitro, and in vivo studies, and in addition to having statistically significant higher analgesic efficacy than thiocolchicoside and acetylsalicylic acid, phenyramidol provides anti-inflammatory efficacy equivalent to Ibuprofen and Dexamethasone through balanced cyclooxygenase enzyme inhibition. Conclusion:Phenyramidol, which contains three pharmacological efficacies that are statistically significant potent analgesic, myorelaxant and anti-inflammatory in studies, is an effective and safe treatment option that provides up to 94% improvement in painful musculoskeletal disorders and is tolerable in 96.8% of patients. Phenyramidol, with its analgesic, myorelaxant and anti-inflammatory effects, is a treatment option that can be used as the first choice in the symptomatic treatment of painful musculoskeletal diseases.

show abstract

The efficacy, safety, and pharmacokinetics of intramuscular and oral phenyramidol in patients with low back pain in an emergency department

Cited by 7 publications

References 4 publications

Three different pharmacological efficacy in a single molecule- phenyramidol

Three different pharmacological efficacy in a single molecule- phenyramidol

Investigation of Electrochemical Oxidation Mechanism, Thermodynamic Parameters and Sensor Design for Analgesic and Relaxant Drug: Phenyramidol in Aqueous Medium by NH₂fMWCNT

Untitled

Contact Info

Product

Resources

About

The efficacy, safety, and pharmacokinetics of intramuscular and oral phenyramidol in patients with low back pain in an emergency department

Cited by 7 publications

References 4 publications

Three different pharmacological efficacy in a single molecule- phenyramidol

Three different pharmacological efficacy in a single molecule- phenyramidol

Investigation of Electrochemical Oxidation Mechanism, Thermodynamic Parameters and Sensor Design for Analgesic and Relaxant Drug: Phenyramidol in Aqueous Medium by NH2fMWCNT

Untitled

Contact Info

Product

Resources

About

Investigation of Electrochemical Oxidation Mechanism, Thermodynamic Parameters and Sensor Design for Analgesic and Relaxant Drug: Phenyramidol in Aqueous Medium by NH₂fMWCNT